BIOMAT Database Logo BIOMAT Database Logo

[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma]. 2006

K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
Charité - Campus Benjamin Franklin, Universitätsmedizin, Berlin. kurt.miller@charite.de

Therapy with Docetaxel for hormone-refractory prostatic carcinoma has for the first time led to an increase in the survival time. Docetaxel has become established as a standard therapy for his indication. Since hormone-refractory prostatic carcinoma is not uniformly defined and is thus for prognosis not a homogeneous entity, the prospects at the start of chemotherapy are uncertain. In the summer of 2005 these questions were addressed in an interdisciplinary consensus conference. It was agreed that the 3-week scheme with 75 mg/m (2) as standard and the indication for symptomatic patients were above question. Opinions differed with regard to the use of chemotherapy in asymptomatic patients. In addition, recommendations for the performance and monitoring of the therapy were formulated.

UI MeSH Term Description Entries
D008297 Male Males
D010348 Patient Care Team Care of patients by a multidisciplinary team usually organized under the leadership of a physician; each member of the team has specific responsibilities and the whole team contributes to the care of the patient. Health Care Team,Interdisciplinary Health Team,Medical Care Team,Multidisciplinary Care Team,Multidisciplinary Health Team,Healthcare Team,Care Team, Health,Care Team, Medical,Care Team, Multidisciplinary,Care Team, Patient,Care Teams, Health,Care Teams, Patient,Health Care Teams,Health Team, Interdisciplinary,Health Team, Multidisciplinary,Healthcare Teams,Interdisciplinary Health Teams,Medical Care Teams,Multidisciplinary Care Teams,Multidisciplinary Health Teams,Patient Care Teams,Team, Health Care,Team, Healthcare,Team, Interdisciplinary Health,Team, Medical Care,Team, Multidisciplinary Care,Team, Multidisciplinary Health,Team, Patient Care,Teams, Interdisciplinary Health
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D043823 Taxoids A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS. Taxanes,Taxoid
D018931 Antineoplastic Agents, Hormonal Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
[Therapy of hormone refractory prostatic carcinoma].
March 1998, Der Urologe. Ausg. A,
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
[Chemotherapy in hormone refractory prostatic carcinoma].
July 1999, Deutsche medizinische Wochenschrift (1946),
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
[Longer life in hormone refractory prostatic carcinoma].
January 2005, Krankenpflege Journal,
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
[Hormone therapy for prostatic carcinoma and hypertrophy].
March 1969, Deutsche medizinische Wochenschrift (1946),
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
[Hormone therapy of prostatic carcinoma].
January 1951, Revista argentina de urologia,
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
[Hormone therapy of prostatic carcinoma].
March 1971, Zeitschrift fur Allgemeinmedizin,
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
[Hormone therapy of prostatic carcinoma].
June 1977, Deutsche medizinische Wochenschrift (1946),
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
[Hormone therapy of prostatic carcinoma].
July 1951, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen,
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.
March 2011, Asian journal of andrology,
K Miller, and K Becker, and F Finke, and G Geiges, and B Göckel-Beining, and D K Hossfeld, and K Miller, and R Osieka, and C Rüssel, and H Tesch, and L Weissbach, and M Wirth, and J M Wolff
Therapeutic alternatives for hormone-refractory prostatic cancer.
February 1992, Seminars in urology,
Copied contents to your clipboard!